title: Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group.
abstract: Untreated patients with Hurler syndrome (MPSIH) experience progressive neurologic deterioration and early death. Allogeneic bone marrow transplantation (BMT) ameliorates or halts this course. The Storage Disease Collaborative Study Group was formed to evaluate the effectiveness and toxicity of BMT. Effectiveness was defined as engrafted survival with continuing cognitive development. Fifty-four patients deficient in leukocyte alpha-L-iduronidase enzyme activity (median age, 1.8 years; range, 0.4 to 7.9) received high-dose chemotherapy with or without irradiation and BMT from HLA-genotypically identical sibling (GIS) or HLA-haploidentical related (HIR) donors between September 16, 1983 and July 14, 1995; all children were included in this report. Thirty-nine of 54 patients (72%) engrafted following the first BMT. The probability of grade II to IV acute graft-versus-host disease (GVHD) at 100 days was 32% for GIS and 55% for HIR patients. The probability of extensive chronic GVHD was 0% for GIS and 24% for HIR patients. The actuarial probability of survival at 5 years was 64% for all patients, 75% for GIS patients, 53% for HIR patients, and 53% for patients with donor marrow engraftment. The baseline Mental Developmental Index (MDI) was examined both for children less than and greater than 24 months of age at BMT. Children transplanted before 24 months had a mean baseline MDI of 78, while those transplanted after 24 months had a mean baseline MDI of 63 (P = . 0002). Both baseline and post-BMT neuropsychologic data were available for 26 of 30 engrafted survivors. Of 14 patients transplanted before 24 months of age, nine demonstrated developmental trajectories that were normal or somewhat slower than normal. In contrast, of 12 patients transplanted after 24 months of age, only three showed developmental trajectories that were normal or somewhat slower than normal (P = .01). For children with a baseline MDI greater than 70, there was a significant correlation between the MDI at follow-up study and leukocyte alpha-L-iduronidase enzyme activity (P = .02). Children were more likely to maintain normal cognitive development if they were fully engrafted following BMT from a donor with homozygous normal leukocyte alpha-L-iduronidase enzyme activity. Children who developed acute GVHD of grade II or worse had significantly poorer cognitive outcomes (P < .009). No difference in the post-BMT MDI was observed between patients whose preparative therapies did (n = 10; radiation dose, 300 to 1,400 cGy) or did not (n = 16) include radiation. We conclude that MPSIH patients, particularly those less than 24 months of age with a baseline MDI greater than 70, can achieve a favorable long-term outcome with continuing cognitive development and prolonged survival after successful BMT from a related donor with homozygous normal enzyme activity.
authors.affiliation: Department of Pediatrics, Division of Bone Marrow Transplant, University of Minnesota, Minneapolis 55455, USA.
authors.forename: C
authors.initials: C
authors.lastname: Peters
authors.forename: E G
authors.initials: EG
authors.lastname: Shapiro
authors.forename: J
authors.initials: J
authors.lastname: Anderson
authors.forename: P J
authors.initials: PJ
authors.lastname: Henslee-Downey
authors.forename: M R
authors.initials: MR
authors.lastname: Klemperer
authors.forename: M J
authors.initials: MJ
authors.lastname: Cowan
authors.forename: E F
authors.initials: EF
authors.lastname: Saunders
authors.forename: P A
authors.initials: PA
authors.lastname: deAlarcon
authors.forename: C
authors.initials: C
authors.lastname: Twist
authors.forename: J B
authors.initials: JB
authors.lastname: Nachman
authors.forename: G A
authors.initials: GA
authors.lastname: Hale
authors.forename: R E
authors.initials: RE
authors.lastname: Harris
authors.forename: M K
authors.initials: MK
authors.lastname: Rozans
authors.forename: J
authors.initials: J
authors.lastname: Kurtzberg
authors.forename: G H
authors.initials: GH
authors.lastname: Grayson
authors.forename: T E
authors.initials: TE
authors.lastname: Williams
authors.forename: C
authors.initials: C
authors.lastname: Lenarsky
authors.forename: J E
authors.initials: JE
authors.lastname: Wagner
authors.forename: W
authors.initials: W
authors.lastname: Krivit
mesh_terms: D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D005260:Female; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D008297:Male; D008059:Mucopolysaccharidosis I / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens